Last updated September 10, 2026
Key finding
Daily total insulin was significantly reduced by Day 77 of semaglutide use versus enrolment (p = 0.01).
Semaglutide versus placebo in adults with type 1 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
Semaglutide versus placebo in adults with type 1 diabetes.
This study evaluated Semaglutide versus placebo in adults with type 1 diabetes.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
Melissa‐Rosina P, Michael AT, Ahmad H. Post-hoc analysis of a double-blinded randomized crossover trial assessing semaglutide in adults with type 1 diabetes. Diabetes, Obesity & Metabolism. 2025;28(1):746-749. doi:10.1111/dom.70185
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Carbohydrate intake, Daily bolus insulin requirements, Total daily insulin dose.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
3
Evidence pairs
321
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Daily bolus insulin requirements
Semaglutide → Daily bolus insulin requirements
Semaglutide → Total daily insulin dose
Semaglutide → Total daily insulin dose
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Insulin Resistance, GLP-1 Receptor Agonists and Carbohydrate intake.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
All studies measuring Carbohydrate intake
Measures Carbohydrate intake as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appear to improve insulin resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Total daily insulin dose
EvidenceScore™ Strong | EvidenceScore™ 76.6 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with generally consistent results and a positive effect signal.
Semaglutide may improve carbohydrate intake.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Carbohydrate intake
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Semaglutide may improve daily bolus insulin requirements.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Daily bolus insulin requirements
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
